Mol Pharmacol
November 2018
Neuropathic pain in patients carrying sodium channel gain-of-function mutations is generally refractory to pharmacotherapy. However, we have shown that pretreatment of cells with clinically achievable concentration of carbamazepine (CBZ; 30 M) depolarizes the voltage dependence of activation in some Na1.7 mutations such as S241T, a novel CBZ mode of action of this drug.
View Article and Find Full Text PDFBackground: Nav1.8 sodium channels, encoded by SCN10A, are preferentially expressed in nociceptive neurons and play an important role in human pain. Although rare gain-of-function variants in SCN10A have been identified in individuals with painful peripheral neuropathies, whether more common variants in SCN10A can have an effect at the channel level and at the dorsal root ganglion, neuronal level leading to a pain disorder or an altered normal pain threshold has not been determined.
View Article and Find Full Text PDFUnlabelled: Voltage-gated sodium channel Nav1.7 is a central player in human pain. Mutations in Nav1.
View Article and Find Full Text PDFObjective: Painful small fibre neuropathy (SFN) represents a significant public health problem, with no cause apparent in one-half of cases (termed idiopathic, I-SFN). Gain-of-function mutations of sodium channel NaV1.7 have recently been identified in nearly 30% of patients with biopsy-confirmed I-SFN.
View Article and Find Full Text PDFSodium channel NaV1.7 is preferentially expressed in dorsal root ganglion (DRG) and sympathetic ganglion neurons. Gain-of-function NaV1.
View Article and Find Full Text PDF